Related Experiment Video
Updated: Mar 14, 2026
Quantifying the Cytotoxicity of Staphylococcus aureus Against Human Polymorphonuclear Leukocytes
Published on: January 3, 2020
Sclareol Protects Staphylococcus aureus-Induced Lung Cell Injury via Inhibiting Alpha-Hemolysin Expression
Ouyang Ping1, Sun Mao1, He Xuewen1
1College of Veterinary Medicine, Sichuan Agriculture University, Chengdu 611130, P.R. China.
Abstract:
Staphylococcus aureus (S. aureus) is a common gram-positive bacterium that causes serious infections in humans and animals. With the continuous emergence of methicillin-resistant S. aureus (MRSA) strains, antibiotics have limited efficacy in treating MRSA infections. Accordingly, novel agents that act on new targets are desperately needed to combat these infections. S. aureus alpha-hemolysin plays an indispensable role in its pathogenicity. In this study, we demonstrate that sclareol, a fragrant chemical compound found in clary sage, can prominently decrease alpha-hemolysin secretion in S. aureus strain USA300 at sub-inhibitory concentrations. Hemolysis assays, western-blotting, and RT-PCR were used to detect the production of alpha-hemolysin in the culture supernatant. When USA300 was co-cultured with A549 epithelial cells, sclareol could protect the A549 cells at a final concentration of 8 μg/ml. The protective capability of sclareol against the USA300-mediated injury of A549 cells was further shown by cytotoxicity assays and live/dead analysis. In conclusion, sclareol was shown to inhibit the production of S. aureus alpha-hemolysin. Sclareol has potential for development as a new agent to treat S. aureus infections.
Insights
Sclareol, a compound from clary sage, reduces Staphylococcus aureus alpha-hemolysin production. This natural agent shows potential for treating S. aureus infections, including MRSA.
Area of Science:
- Microbiology
- Pharmacology
- Natural Products Chemistry
Background:
- Staphylococcus aureus (S. aureus) causes significant human and animal infections.
- Antibiotic resistance, particularly methicillin-resistant S. aureus (MRSA), limits treatment options.
- S. aureus alpha-hemolysin is a key virulence factor contributing to pathogenicity.
Purpose of the Study:
- To investigate the effect of sclareol on S. aureus alpha-hemolysin production.
- To evaluate sclareol's protective capacity against S. aureus-induced host cell damage.
Main Methods:
- Sclareol was tested against S. aureus USA300 at sub-inhibitory concentrations.
- Alpha-hemolysin secretion was measured using hemolysis assays, western-blotting, and RT-PCR.
- Cytotoxicity and live/dead assays assessed protection of A549 epithelial cells.
Main Results:
- Sclareol significantly decreased alpha-hemolysin secretion in S. aureus USA300.
- Sclareol protected A549 epithelial cells from S. aureus-mediated injury at 8 μg/ml.
- Inhibition of alpha-hemolysin production was confirmed by multiple methods.
Conclusions:
- Sclareol effectively inhibits Staphylococcus aureus alpha-hemolysin production.
- Sclareol demonstrates potential as a novel therapeutic agent for S. aureus infections.
- Further development of sclareol may offer a new strategy against antibiotic-resistant strains.
